Medregen’s lead drug (MRG-001) is a novel drug developed for the purpose of organ repair/regeneration and immunomodulation.
Tissue injury caused by disease or trauma leads to cell death and organ dysfunction. MRG-001 administration mobilizes stem cells and immunomodulatory cells into the peripheral circulation that are attracted by chemokines secreted by injured organs, known as stromal cell-derived factor 1. Stem cells migrate to the injured tissue and are able to replace injured endothelium by means of angiogenesis and replace dead cells by differentiating into tissue specific cell types. Additionally, immunomodulatory cells such as anti-inflammatory M2-type macrophages and FOXP3+ regulatory T-cells are also recruited to the site of injury to minimize inflammation.
Medregen provided compassionate use of MRG-001 in several diseases. MedRegen evaluates compassionate use requests on a case-by-case basis, considering the specific medical needs and circumstances of the patient. Each request is carefully reviewed to ensure alignment with ethical standards and regulatory guidelines.
MedRegen has been very active in exploring MRG-001’s potential in other pre-clinical disease indications as demonstrated here below.
.
